Literature DB >> 15265826

Evidence for abnormal translational regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase activity in the hyp-mouse.

Baozhi Yuan1, Yina Xing, Ron L Horst, Marc K Drezner.   

Abstract

Hyp-mice exhibit abnormal regulation of 25-hydroxyvitamin D [25(OH)D]-1alpha-hydroxylase activity. Previous observations suggest such aberrant modulation is posttranscriptional. To investigate this possibility further, we examined whether hyp-mice manifest abnormal translation of 25(OH)D-1alpha-hydroxylase mRNA. We compared phosphate, parathyroid, and calcitonin effects on renal 25(OH)D-1alpha-hydroxylase protein as well as mRNA and enzyme activity in normal and hyp-mice. We assayed protein by Western blots, mRNA by real-time RT-PCR, and enzyme activity by measuring 1,25-dihydroxyvitamin D production. Although phosphate-depleted mice exhibited enhanced enzyme function, with significantly increased mRNA and protein expression, hyp-mice comparably increased mRNA but failed to augment enzyme activity, concordant with an inability to increase protein expression. PTH stimulation increased mRNA and protein expression as well as enzyme activity in normal mice but in hyp-mice, despite effecting mRNA enhancement, did not increment enzyme function or protein. The inability of hypophosphatemia and PTH to increase 25(OH)D-1alpha-hydroxylase activity and protein expression in hyp-mice was not universal because calcitonin stimulation was normal, suggesting proximal convoluted tubule localization of the defect. These data, in accord with absent undue enhancement of protein expression in hyp-mice treated with protease inhibitors, establish that abberrant regulation of vitamin D metabolism results from abnormal translational activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265826     DOI: 10.1210/en.2004-0192

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  16 in total

Review 1.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

2.  Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.

Authors:  Hua Li; Aline Martin; Valentin David; L Darryl Quarles
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-12-07       Impact factor: 4.310

3.  Fibroblast Growth Factor 23 as Regulator of Vitamin D Metabolism.

Authors:  Shinya Nakatani; Masaaki Inaba; Ayumi Nakatani; Katsuhito Mori; Masanori Emoto; Mohammed S Razzaque
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Chronic kidney disease and diabetes mellitus predict resistance to vitamin D replacement therapy.

Authors:  Hala M Alshayeb; Barry M Wall; Arif Showkat; L Darryl Quarles; Therese Mangold
Journal:  Am J Med Sci       Date:  2013-04       Impact factor: 2.378

5.  Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation.

Authors:  Daniel Zehnder; Marcus Quinkler; Kevin S Eardley; Rosemary Bland; Julia Lepenies; Susan V Hughes; Neil T Raymond; Alexander J Howie; Paul Cockwell; Paul M Stewart; Martin Hewison
Journal:  Kidney Int       Date:  2008-09-10       Impact factor: 10.612

6.  Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.

Authors:  Baozhi Yuan; Jian Q Feng; Stephen Bowman; Ying Liu; Robert D Blank; Iris Lindberg; Marc K Drezner
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

7.  Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia.

Authors:  Baozhi Yuan; Masanori Takaiwa; Thomas L Clemens; Jian Q Feng; Rajiv Kumar; Peter S Rowe; Yixia Xie; Marc K Drezner
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

8.  Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.

Authors:  Teruyo Nakatani; Mutsuko Ohnishi; M Shawkat Razzaque
Journal:  FASEB J       Date:  2009-07-07       Impact factor: 5.191

9.  FGFR3 and FGFR4 do not mediate renal effects of FGF23.

Authors:  Shiguang Liu; Luke Vierthaler; Wen Tang; Jianping Zhou; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2008-08-27       Impact factor: 10.121

10.  Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites.

Authors:  Bing Dai; Valentin David; Hala M Alshayeb; Arif Showkat; Geeta Gyamlani; Ronald L Horst; Barry M Wall; L Darryl Quarles
Journal:  Kidney Int       Date:  2012-06-27       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.